XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Metrics to compare | XRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −1.7x | −0.5x | |
PEG Ratio | −0.02 | 0.03 | 0.00 | |
Price / Book | 1.5x | 0.9x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.2x | |
Upside (Analyst Target) | - | 70.4% | 47.6% | |
Fair Value Upside | Unlock | 10.1% | 6.1% | Unlock |